GlassScriptPhysician profile
Taylor A Olson
NPI 1770103277
$1,178.96
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.27 · 2022: $304 · 2023: $765 · 2024: $73.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $444.42 | 2022-2023 | Cabenuva, Rukobia, Dovato |
| Novo Nordisk INC | $243.31 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $104.99 | 2023-2024 | |
| Antares Pharma, INC. | $63.87 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.05 | 2023 | Caplyta |
| Gilead Sciences, INC. | $54.60 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $51.10 | 2023 | Dificid, Pifeltro, Delstrigo |
| Idorsia Pharmaceuticals US INC | $33.33 | 2023 | Quviviq |
| Janssen Biotech, INC. | $24.34 | 2023 | Symtuza |
| Glaxosmithkline, LLC. | $23.91 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Supernus Pharmaceuticals, INC. | $21.98 | 2024 | Qelbree |
| Hologic Sales and Service, LLC | $20.41 | 2022 | |
| Pfizer INC. | $16.84 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.